Osimertinib, sold under the brand name Tagrisso,[1] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[2][3] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (see Receptor tyrosine kinases). See also Osimertinib.
Osimertinib preferentially binds irreversibly to mutated epidermal growth factor receptor proteins, particularly those with more common mutations in lung cancer such as L858R mutation or an exon 19 deletion.[4]
(6lud).
.
